Zydus Lifesciences reported a robust performance for the second quarter ended September 30, 2025, with net profit rising over 38 percent to INR 1,258.6 crore, compared to INR 911.2 crore in the same quarter last year. The company’s total revenue from operations grew nearly 17 percent year-over-year to INR 6,123.2 crore, up from INR 5,237 crore. EBITDA increased 38 percent to INR 2,015.8 crore, while the EBITDA margin improved by 500 basis points to 32.9 percent.

The company also announced plans to raise around INR 5,000 crore through various routes, including Qualified Institutions Placement (QIP), rights issue, preferential allotment, private placement, or a combination thereof.

Research and development (R&D) expenditure stood at INR 482 crore, representing 7.9 percent of total revenues, while capital expenditure for organic growth was INR 491.1 crore.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, said the results reflect the company’s strong execution across geographies and verticals, supported by growth in the US and India formulations businesses, international markets, and strategic acquisitions in wellness and MedTech.

US formulations revenue rose 13.5 percent to INR 2,743.7 crore, accounting for 45 percent of total business, while India formulations grew 8.4 percent to INR 1,593.1 crore. The international formulations segment recorded 39.4 percent growth to INR 751.3 crore, and the consumer wellness business grew 30.7 percent to INR 637.4 crore. The API business increased 23.3 percent to INR 147.2 crore, and the MedTech segment, driven by acquisitions, contributed INR 153.2 crore, or nearly three percent of total revenue.

For the first half of FY2025, Zydus reported a 17 percent rise in net profit to INR 2,725.4 crore, with total revenue up 11 percent to INR 12,696.9 crore. The company’s EBITDA grew 16 percent year-over-year to INR 4,104.3 crore, with an improved margin of 32.3 percent.

Zydus also completed the acquisition of UK-based Comfort Click Limited and its subsidiaries in Ireland, the US, and India — marking Zydus Wellness’ first international acquisition and its entry into the vitamins, minerals, and supplements (VMS) segment.